Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

2017 Nucleic Acid Testing (NAT) Market in 33 Countries: Sales Forecasts and Supplier Shares--Infectious and Genetic Diseases, Cancer, Forensic and Paternity Testing--Competitive Strategies, Instrumentation and Technology Review, Opportunities

ReportBuyer
Posted on: 30 Nov 16

PR Newswire

LONDON, Nov. 29, 2016

LONDON, Nov. 29, 2016 /PRNewswire/ -- This new 33-country survey from VPGMarketResearch.com contains over 1,600 pages, 350 tables, and provides granular data and analysis not available from any other source. The report is designed to help current suppliers and potential market entrants identify and evaluate major business opportunities emerging in the molecular diagnostics market during the next five years.

Highlights

- Supplier sales and market shares in major countries
- Five-year test volume and sales forecasts
- Strategic profiles of market players and start-up firms developing innovative technologies and products
- Emerging technologies
- Review of molecular diagnostic analyzers
- Specific product and business opportunities for instrument and consumable suppliers

Rationale

The molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of cost-effective and automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new molecular technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostic companies during the next five years.

Geographic Coverage

Australia, Austria, Belgium, Bulgaria, Canada, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Japan, Latvia, Lithuania, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, UK, US

Market Segmentation Analysis

- Sales and market shares of key suppliers of molecular diagnostic reagent
kits and components in major markets.

- Five-year test volume and sales forecasts for major applications, including:

&nbsp &nbsp - Infectious Diseases        &nbsp &nbsp - Forensic Testing
&nbsp &nbsp - Cancer&nbsp               &nbsp                  &nbsp - Paternity Testing/HLA Typing
&nbsp &nbsp - Genetic Diseases             &nbsp &nbsp - Others

- Five-year test volume and sales projections for over 30 NAT assays.

- Analysis of the sequencing market, including:

- Industrial
- Academic
- Government
- Commercial

- Market segmentation analysis, including review of the market dynamics,
trends, structure, size, growth and major suppliers.

Product/Technology Review

- Comparison of leading molecular diagnostic ;analyzers marketed by Abbott, Beckman Coulter, BD, Bio-Rad, Gen-Probe, Roche, Tecan and other suppliers.

- Extensive review of molecular diagnostic technologies, test formats, detection methodologies, trends in testing automation and over 30 target/signal amplification methods, including:

- PCR     - bDNA
- SDA     - NASBA
- TMA    - SSSR, and others
- LCR

- Universities and research centers developing new molecular diagnostic technologies and products.

Competitive Assessments

- Extensive strategic assessments of major suppliers and emerging market entrants, including their sales, product portfolios, marketing tactics, collaborative arrangements and new technologies/products in R&D.

- Companies developing and marketing molecular diagnostics products, by test and application.

Opportunities and Strategic Recommendations

- Specific new product development opportunities with potentially significant market appeal during the next five years.

- Design criteria for new products.

- Alternative market penetration strategies.

- Potential market entry barriers and risks.

- Business planning issues and concerns.

Contains 1,600 pages and 350 tables


Download the full report: https://www.reportbuyer.com/product/4385287/

About Reportbuyer
Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers
http://www.reportbuyer.com

For more information:
Sarah Smith
Research Advisor at Reportbuyer.com
Email: query@reportbuyer.com
Tel: +44 208 816 85 48
Website: www.reportbuyer.com

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/2017-nucleic-acid-testing-nat-market-in-33-countries-sales-forecasts-and-supplier-shares--infectious-and-genetic-diseases-cancer-forensic-and-paternity-testing--competitive-strategies-instrumentation-and-technology-review-o-300370178.html

SOURCE ReportBuyer

PR Newswire
www.prnewswire.com

Last updated on: 30/11/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.